Fertility after discontinuation of treatment with an oral contraceptive containing 30 μg of ethinyl estradiol and 2 mg of dienogest

被引:25
|
作者
Wiegratz, Inka
Mittmann, Katrin
Dietrich, Horst
Zimmermann, Thomas
Kuhl, Herbert
机构
[1] Goethe Univ Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany
[2] Jenapharm GmbH & Co KG, Jena, Germany
关键词
oral contraceptives; ethinyl estradiol; dienogest; fertility regain; conception rate;
D O I
10.1016/j.fertnstert.2005.11.052
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To examine the conception rate after cessation of a combination of 30 mu g ethinyl E-2 and 2 mg dienogest (EE/DNG). Design: Prospective observational study. Setting: Population-based cohort in Germany. Patient(s): Women who wished to become pregnant after cessation of an oral contraceptive (EE/DNG). Intervention(s): None. Main Outcome Measure(s): Cumulative conception rate within 1 year after termination of EE/DNG and time to pregnancy. Result(s): After 1 year follow-up, the cumulative pregnancy rate was 86.6% (full analysis set; n = 706). When all participants with complete data were analyzed (n = 652), the cumulative pregnancy rate was 94.0%. More than 15% of the patients conceived in each of the first three cycles after termination of EE/DNG; the mean time to pregnancy was 3.5 cycles. The preceeding duration of treatment with EE/DNG did not influence the conception rate. Except in the youngest age group (16-18 years), a certain delay was observed in the other age groups. Conclusion(s): The present prospective study revealed only a slight delay in regaining fertility during the first three cycles after cessation of EE/DNG. Thereafter, the cumulative rate of conception did not differ form that observed in fertile women who attempted to become pregnant without prior conception.
引用
收藏
页码:1812 / 1819
页数:8
相关论文
共 50 条
  • [1] Modulation of ovarian function by an oral contraceptive containing 30 mu g ethinyl estradiol in combination with 2.00 mg dienogest
    Spona, J
    Feichtinger, W
    Kindermann, C
    Moore, C
    Mellinger, U
    Walter, F
    Graser, T
    CONTRACEPTION, 1997, 56 (03) : 185 - 191
  • [2] Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 μg of ethinyl estradiol on the human endometrium
    Lüdicke, F
    Johannisson, E
    Helmerhorst, FM
    Campana, A
    Foidart, JM
    Heithecker, R
    FERTILITY AND STERILITY, 2001, 76 (01) : 102 - 107
  • [3] Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol
    Paoletti, AM
    Lello, S
    Fratta, S
    Orrù, M
    Ranuzzi, F
    Sogliano, C
    Concas, A
    Biggio, G
    Melis, GB
    FERTILITY AND STERILITY, 2004, 81 (03) : 645 - 651
  • [4] Fertility after discontinuation of the dienogest-containing oral contraceptive Valette®.: First data of an ongoing study
    Zimmermann, T
    Dietrich, H
    Wisser, KH
    Münch, C
    DRUGS OF TODAY, 1999, 35 : 89 - 95
  • [5] Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 mu g ethinyl estradiol and 2.00 mg dienogest on the hemostatic system
    Spona, J
    Feichtinger, W
    Kindermann, C
    Schneider, B
    Mellinger, U
    Walter, F
    Moore, C
    Graser, T
    CONTRACEPTION, 1997, 56 (02) : 67 - 75
  • [6] Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone
    Ahrendt, Hans-Joachim
    Nisand, Israel
    Bastianelli, Carlo
    Gomez, Maria Angeles
    Gemzell-Danielsson, Kristina
    Urdl, Wolfgang
    Karskov, Birgit
    Oeyen, Luc
    Bitzer, Johannes
    Page, Geert
    Milsom, Ian
    CONTRACEPTION, 2006, 74 (06) : 451 - 457
  • [7] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use
    Wiegratz, Inka
    Stahlberg, Skadi
    Manthey, Torsten
    Saenger, Nicole
    Mittmann, Katrin
    Palombo-Kinne, Ernesta
    Mellinger, Uwe
    Lange, Evelyn
    Kuhl, Herbert
    CONTRACEPTION, 2010, 81 (01) : 57 - 61
  • [8] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters:: conventional vs. extended-cycle use
    Saenger, Nicole
    Stahlberg, Skadi
    Manthey, Torsten
    Mittmann, Katrin
    Mellinger, Uwe
    Lange, Evelyn
    Kuhl, Herbert
    Wiegratz, Inka
    CONTRACEPTION, 2008, 77 (06) : 420 - 425
  • [9] Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg drospirenone
    Milsom, I.
    Lete, I.
    Bjertnaes, A.
    Rokstad, K.
    Lindh, I.
    Gruber, C. J.
    Birkhaeuser, M. H.
    Aubeny, E.
    Knudsen, T.
    Bastianelli, C.
    HUMAN REPRODUCTION, 2006, 21 (09) : 2304 - 2311
  • [10] Contraceptive efficacy and acceptability of a monophasic oral contraceptive containing 30 μg ethinyl estradiol and 150 μg desogestrel in Latin-American women
    Comparato, MR
    Yabur, JA
    Bajares, M
    ADVANCES IN CONTRACEPTION, 1998, 14 (01) : 15 - 26